Report on OpportunityAnalyzer: Celiac Disease Market Trend, Growth, Opportunity Analysis and Forecast to 2023
There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications. The anticipated launch of Alba/Teva's larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie's latiglutenase in 2019 and 2020 in the US...
View full press release